Congestive Heart Failure (CHF) Market in 8MM – Market Outlook, Market Assessment and Market Forecast (2023-2030)

Congestive Heart Failure (CHF) – Report Overview

Pacific Business Consulting’s “Congestive Heart Failure (CHF) Market in 8MM – Market Outlook, Market Assessment and Market Forecast (2023-2030)” report offers a comprehensive exploration of Congestive Heart Failure (CHF), encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

The global market size for congestive heart failure (CHF) drugs reached US$ 6.5 billion in 2022 and is poised to grow at a compound annual growth rate (CAGR) exceeding 10% from 2023 to 2030. This growth is attributed to a robust product pipeline, an aging population, and increased research and development in drug development. The rising prevalence of diseases such as obesity, diabetes, hypertension, chronic pulmonary diseases, and renal disease, considered prominent co-morbidities of CHF, is another significant factor driving market expansion. However, over the forecast period, the high saturation of generic drugs is expected to slow down growth.

CHF is a global health concern with high morbidity and mortality rates. The Global Health Data Exchange registry reported a global prevalence of approximately 64.34 million cases, with approximately 5.5 million cases in the U.S. in 2022.

Commonly used treatment options include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor II blockers, diuretics, and beta-blockers. Additional therapies such as amiodarone, aldosterone antagonists, antiaggregants, anticoagulants, diuretics, nitrates, and calcium antagonists are also utilized for CHF treatment. After more than a decade of a scarcity of sustainable new therapies, the U.S. FDA approved new classes of agents for CHF treatment, including Entresto (sacubitril/valsartan) and Corlanor (ivabradine).

The expanded approval of Jardiance is anticipated to compete with Entresto and Farxiga in the heart failure with preserved ejection fraction (HFpEF) segment. The CHF market is expected to witness growth with recent drug approvals and upcoming therapies in various stages of development.

Key companies in the Congestive Heart Failure (CHF) market include Novartis, Boehringer Ingelheim, Bayer, Merck, AstraZeneca, Amgen, Eli Lilly, Otsuka Pharmaceutical, Cytokinetics, Novo Nordisk, Lexicon Pharmaceuticals, Intra-Cellular Therapies, BioCardia, and Bristol-Myers Squibb.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Congestive Heart Failure (CHF) market. It also delves into the analysis of present and prospective market competition within the Congestive Heart Failure (CHF) market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Congestive Heart Failure (CHF) market across the 8MM (Eight Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Congestive Heart Failure (CHF) market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

1. Executive Summary: Congestive Heart Failure (CHF)
   • Global Market Outlook: Congestive Heart Failure (CHF)
2. Competitive Intelligence Analysis: Congestive Heart Failure (CHF)
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis: Congestive Heart Failure (CHF)
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Disease Overview: Congestive Heart Failure (CHF)
   • Disease Etiology
   • Pathophysiology
   • Risk Factors
   • Treatment Algorithm
7. Congestive Heart Failure (CHF): Key Marketed Products Profile – Major Approved Products
   • Product Profile
   • Regulatory Milestones
   • Safety and Efficacy
   • Clinical Development
8. Congestive Heart Failure (CHF): Promising Pipeline Candidates – Major Products in Late Stage of Development
   • Product Description
   • Safety and Efficacy
   • Research and Development
9. Regulatory Landscape
10. Congestive Heart Failure (CHF): Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
11. S. Congestive Heart Failure (CHF) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
12. K. Congestive Heart Failure (CHF) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
13. Germany Congestive Heart Failure (CHF) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
14. France Congestive Heart Failure (CHF) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
15. Italy Congestive Heart Failure (CHF) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
16. Spain Congestive Heart Failure (CHF) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
17. Japan Congestive Heart Failure (CHF) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
18. China Congestive Heart Failure (CHF) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

20. Assumptions and Acronyms Used
21. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
22. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China

Copyrights and Disclaimer